Regulatory considerations for vaccine development, talk 2 clinical regulatory considerations (part 2 of 2) /

Saved in:
Bibliographic Details
Other Authors: Schrager, Lewis K. (Speaker)
Format: Electronic Video
Language:English
Published: London : Henry Stewart Talks, 2015.
Series:Henry Stewart talks. Biomedical & life sciences collection. Vaccines.
Subjects:
Online Access:https://hstalks.com/bs/3170/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000ngm a2200000 a 4500
001 HST4161
003 UkLoHST
006 m c
007 cr|cna|||a||||
007 vz|czazum
008 151211s2015 enk|||||||||||s|||v|eng d
028 5 0 |a 4161  |b Henry Stewart Talks 
035 |a (UkLoHST)3170 
040 |a UkLoHST  |b eng  |c UkLoHST 
100 1 |a Schrager, Lewis K.,  |u (Aeras, USA)  |4 spk  |9 100421 
245 1 0 |a Regulatory considerations for vaccine development, talk 2  |h [electronic resource] :  |b clinical regulatory considerations (part 2 of 2) /  |c Lewis K. Schrager. 
246 3 |a Clinical regulatory considerations. Part 2 
260 |a London :  |b Henry Stewart Talks,  |c 2015. 
300 |a 1 online resource (1 streaming video file (35 min.) :  |b color, sound). 
490 1 |a Vaccines : principles, recent developments and future directions,  |x 2056-452X 
500 |a Animated audio-visual presentation with synchronized narration. 
500 |a Title from title frames. 
505 0 |a Contents: Biological License Application (BLA) pathways -- Traditional, accelerated approval, "Animal Rule" -- Programs that accelerate the clinical testing (IND) and review (BLA) processes -- Fast track designation -- Breakthrough designation -- Priority review -- The package insert -- Pediatric study requirements -- Adjuvants -- Adaptive trial design from a regulatory perspective -- Developing vaccines for global infectious diseases. 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
610 1 0 |a United States.  |b Food and Drug Administration.  |9 100422 
650 0 |a Vaccines industry  |x Government policy  |z United States.  |9 100423 
650 0 |a Vaccines  |x Development.  |9 100424 
650 2 |a Animal Testing Alternatives.  |9 100425 
650 2 |a Biological Products  |x standards.  |9 100426 
650 2 |a Clinical Trials as Topic  |x legislation & jurisprudence.  |9 100427 
650 2 |a Drug Approval  |x methods.  |9 100428 
650 2 |a Drug Evaluation, Preclinical.  |9 100429 
650 2 |a Drug Industry  |x legislation & jurisprudence.  |9 100430 
650 2 |a Investigational New Drug Application  |x legislation & jurisprudence.  |9 100431 
650 2 |a Investigational New Drug Application  |x methods.  |9 100432 
650 2 |a United States Food and Drug Administration  |x legislation & jurisprudence.  |9 100433 
650 2 |a United States Food and Drug Administration  |x standards.  |9 100434 
650 2 |a Vaccines  |x standards.  |9 100435 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Vaccines.  |9 100436 
856 4 0 |u https://hstalks.com/bs/3170/ 
856 4 2 |u https://hstalks.com/bs/p/923/  |3 Series 
999 |c 214835  |d 214834